CAPR News and Press, Capricor Therapeutics Inc. From 12/17/19

LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.  (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today anno...

Gainers: Mirum Pharmaceuticals (NASDAQ: MIRM )  +110% . More news on: Mirum Pharmaceuticals, Inc., Axsome Therapeutics, Inc., The Goldfield Corporation, Stocks on the move, Read more ...

Gainers:  Genesco (NYSE: GCO )  +33% . More news on: Genesco Inc., Wellesley Bancorp, Inc., Big Lots, Inc., Stocks on the move, Read more ...

Sage Therapeutics SAGE  -62%  after SAGE-217 flunks MDD study. More news on: Capricor Therapeutics, Inc., Axsome Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...

Solid Biosciences (NASDAQ: SLDB ) reports that the FDA has placed its Phase 1/2 clinical trial, IGNITE DMD , evaluating lead gene therapy candidate SGT-001 in Duchenne muscular dystrophy (DMD) patients on clinical hold after a participant experienced a serious adverse event related to the...

Capricor Therapeutics, Inc. (CAPR) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants AJ Bergmann – Chief Financial Officer Linda Marbán – President and Chief Executive Officer Conference Call Participants Joanne Lee – ...

Capricor Therapeutics (NASDAQ: CAPR ): Q3 GAAP EPS of -$0.43 beats by $0.25 . Revenue of $0.14M (-36.4% Y/Y) misses by $0.08M . Press Release More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR...

LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its thi...

Call Scheduled for Thursday, October 24 th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duche...